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Objective: This study was undertaken to determine maximum tolerated dose and toxicity of intraoperative intra-
cavitary hyperthermic cisplatin perfusion with amifostine after extrapleural pneumonectomy for malignant pleu-
ral mesothelioma.
Methods: Patients with mesothelioma were prospectively enrolled. Those with resectable disease received ami-
fostine and 1-hour hyperthermic cisplatin perfusion of ipsilateral hemithorax and abdomen. Morbidity, recur-
rence, and survival were recorded.
Results: Forty-two patients were enrolled; 29 underwent resection (operative mortality 7%, 2/29). Median age
was 57 years. Eighteen were in pathologic stage I or II; 11 were in stage III. Median hospitalization was 15 days.
Common complications were atrial fibrillation (66%, 19 patients), deep venous thrombosis (31%, 9 patients),
and grade 3þrenal toxicity (31%, 9 patients). Feasibility was determined. Renal toxicity was unrelated to cisplatin
dose, with no maximum tolerated dose determined. Overall median survival was 17 months (resected 20 months,
unresected 10 months). Median survivals were 26 months for patients receiving higher cisplatin doses and 16
months for those receiving lower doses (P ¼ .35). Survival was significantly longer with negative extrapleural
nodes (31 vs 14 months, P ¼ .0115) and early stage (all resected 35 months for stage I–II vs 14 months for stage
III, P ¼ .0022, epithelial 39 months for stage I–II vs 15 months for stage III, P ¼ .0072).
Conclusion: Early stage and negative extrapleural lymph nodes were associated with prolonged survival. Single-
dose amifostine did not protect adequately against cisplatin-induced renal toxicity. Additional cytoprotective
strategies are needed to allow determination of cisplatin maximum tolerated dose.Despite aggressive surgery plus chemotherapy and chest
radiation, malignant pleural mesothelioma (MPM) remains
a disease characterized by relentless local progression and
locoregional recurrence in most patients undergoing surgical
resection.1-5 Extrapleural pneumonectomy (EPP) represents
the most extensive form of cytoreductive surgery possible,
but other techniques, such as locoregional chemotherapy
in conjunction with surgery either intraoperatively or post-
operatively, have been attempted for various malignancies,
including MPM, with manageable toxicity and improved
local control and survival.6-11
Cisplatin has been used extensively for locoregional per-
fusion in thoracic malignancies. We have recently published
a phase I and II study of intraoperative locoregional cisplatin
perfusion after pleurectomy for MPM that determined 225
mg/m2 to be themaximum tolerated dose (MTD), with a sug-
gested survival advantage for patients who received higher
doses of cisplatin within the limitations of a nonrandomized
trial.6 The MTD for intraoperative locoregional cisplatin in
the setting of EPP, however, has not been fully explored.
The goal of achieving enhanced local drug delivery at the
site of resection in the thorax by using higher doses of cis-
platin has been limited by renal toxicity resulting from sys-
temic absorption of the cisplatin. The relative effectiveness
of pharmacologic renal cytoprotective strategies will likely
impact the cisplatin MTD achieved in phase I studies. The
use of an effective cytoprotective agent to preserve the kid-
ney is appealing, particularly in the setting of EPP, in which
traditional use of postoperative hydration to limit renal
toxicity may be limited to avoid excessive contralateral
lung fluid retention and resulting hypoxia in the postopera-
tive period.
Our previous studies with intraoperative hyperthermic
cisplatin (IOHC) have used sodium thiosulfate as a protec-
tive agent. Although sodium thiosulfate provides excellent
renal protection, its mechanism of action involves inactiva-
tion of cisplatin and therefore may compromise cisplatin’s
potential therapeutic effect. For this reason, it is of interest
to explore alternative strategies for renal protection in the
setting of IOHC.
Amifostine (Ethyol, ALZA Corporation, Mountain View,
Calif) has been added in various systemic chemotherapeutic
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protocols as a cytoprotective agent in regimens involving
alkylating and platinum-related agents for head and neck,
thoracic, and gynecologic malignancies, as well as mela-
noma.12-16 The preferential 100-fold uptake of amifostine
by normal cells results in selective protection of normal
tissues by intracellular radical salvage and binding of
chemotherapeutic agents, with preservation of tumoricidal
properties of cisplatin in the malignant cells. Single-dose
amifostine has been used in cisplatin-based protocols and
in this study was dosed according to the American Society
of Clinical Oncology Clinical Practice Guidelines.16
We conducted this phase I study to determine the feasibil-
ity, toxicity, and MTD of cisplatin in patients undergoing
intraoperative intrathoracic and intraperitoneal hyperthermic
perfusion of cisplatin after EPP and after intravenous admin-
istration of amifostine.
MATERIALS AND METHODS
Eligible Patients
Patients who came to Brigham and Women’s Hospital with a confirmed
diagnosis of MPM and who were candidates for EPP were considered for
enrollment in the institutional review board– and scientific review commit-
tee–approved protocol after appropriate consent was obtained. Appropriate
patients for enrollment were men or nonpregnant women (older than 16
years) who were good operative candidates with good functional status
and had no significant comorbidities or cancer other than MPM, which
was confined to the ipsilateral hemithorax as determined by computed tomo-
graphic scan and magnetic resonance imaging.1 Postoperative predicted
forced expiratory value in 1 second greater than 0.8 L, preoperative creati-
nine less than 2.0 mg/dL, and availability for follow-up were required.
Patients who had received neoadjuvant chemotherapy or radiation were
excluded. Appropriate candidates were registered with the Quality Assur-
ance for Clinical Trials office during the preoperative visit. Three patients
were scheduled at each dose level, followed by escalation of the dose for
the next 3 patients provided there were no dose-limiting toxicities, addition
of 3 patients at the same dose in case of 1 dose-limiting toxicity, and de-
escalation of the dose if 2 or more dose-limiting toxicities were observed
among 6 patients. Dose-limiting toxicities were defined as any grade 3 or
higher complication not definitively caused by surgery according to the
National Cancer Institute common toxicity criteria version 2.0.
Surgical Technique and IOHC
Those patients who had less than 1 cm3 residual tumor, as evaluated with
visual inspection by the operating surgeon, after the tumor was resected and
before the diaphragmatic and pericardial reconstructions were performed,
received the IOHC cisplatin perfusion for 1 hour in the chest and abdomen
at 42C. To reduce the renal toxicity of cisplatin and allow maximal dose
escalation of cisplatin, intravenous amifostine was administered before
the initiation of the intraoperative chemotherapy at a dose of 910 mg/m2
according to the American Society of Clinical Oncology Clinical Practice
Guidelines.16 Intravenous fluids, dopamine, mannitol, and furosemide
were used to maintain perfusion pressure and urinary output (at 100 mL/
h) during the intrapleural cisplatin treatment and for 1 hour thereafter. At
the conclusion of the IOHC perfusion, all the chemotherapy perfusate
was evacuated, and the reconstructions were performed. Details of the tech-
nique have been described elsewhere.6,17
Follow-up
Patients were followed up after entry into the trial, and postoperative
morbidity and mortality were recorded. Laboratory tests were done daily
in the immediate postoperative period and at 2 weeks and 1 month postop-
eratively. Lower extremity venous ultrasonography was performed on post-
operative day 7 or before discharge, according to the institutional review
board–approved protocol, to evaluate for deep venous thrombosis. Echocar-
diograms were obtained at 1, 3, and 6 postoperative months to assess heart
function, and computed tomography of the chest and abdomen was per-
formed at least every 6 months, or sooner if symptoms arose, to monitor
for recurrence of MPM. The recurrence-free interval after surgery and sur-
vival were recorded. Although no adjuvant therapy was included in the pro-
tocol, some patients received additional treatment off protocol at the
discretion of their local physicians according to their clinical presentations
and courses.
Statistical Analysis
The sample size of 19 to 53 patients was calculated by the institutional
statistician and approved by the scientific review committee and institu-
tional review board. The time to disease recurrence was defined as the inter-
val between the date of surgery and the date of the first radiographically
confirmed clinical recurrence. Survival was defined as the interval between
the date of surgery and date of last follow-up or date of death. Kaplan–Meier
curves of survival and time to recurrence were constructed 48 months after
the last patient was registered. The log-rank statistic was used for univariate
analysis of prognostic factors.
RESULTS
Between August 2001 and July 2002, a total of 42 patients
were enrolled in the protocol. Thirteen patients were found
at thoracotomy to have unresectable disease (9 with chest
wall invasion, 3 with chest wall and mediastinal invasion,
and 1 with cardiac invasion). Twenty-nine patients had their
MPM resected to smaller than 1 cm3 (Table 1). There were
22 male and 7 female patients, with a median age of 57
years. The stage distribution was as follows: 5 patients
with stage I disease, 13 with stage II, and 11 with stage
III. Twenty-four patients had epithelial disease, and 5 pa-
tients had nonepithelial tumors. All the patients who under-
went resection received amifostine and successfully
underwent hyperthermic cisplatin lavage as previously
described elsewhere.6
Morbidity
There were 2 postoperative deaths among the 29 patients
who underwent resection (7%). One patient died of a pulmo-
nary embolus on postoperative day 11; the other died of
a bronchopleural fistula on postoperative day 57. Median
hospitalization for patients who underwent resection was
15 days (Table 2).
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19 patients (66%) having atrial fibrillation develop during
hospitalization. Deep venous thrombosis was seen in 9
patients (31%). Three patients had pulmonary emboli.
Reoperations for infections, bleeding, or diaphragmatic
patch complications occurred in 6 of 29 patients (21%).
Four patients (14%) had adult respiratory distress syn-
drome, and 2 required tracheostomy and feeding tubes.
Three patients (10%) had empyema develop; 1 required
a Clagett window, and the other two were treated with
video-assisted thoracoscopy and irrigation.
Maximum Tolerated Dose
The dose escalation, de-escalation, and revision of the
protocol after consultationwith the institutional reviewboard
in response to grade 3þ renal toxicity are shown in
Table 3. Overall, grade 3þ renal toxicity developed in 9
patients (31%), with 2 requiring temporary renal dialysis
and 1 with permanent renal failure (Table 2). The median
time to peak creatinine was 5 days, and themedian time to re-
covery to baseline creatinine level was 16.5 days. This renal
toxicity was unrelated to cisplatin dose and occurred at low
and high cisplatin dose levels, resulting in premature closure
of the protocol to accrual without determination of MTD.
Overall Survival
The patients were entered into the study from August
2001 to July 2002. At the time of this analysis, 6 patients
remained alive and 36 had died. All patients with unresect-
able disease have died. The overall median survival for the
42 patients enrolled in the protocol, both those with resect-
able disease and those with unresectable disease, was 17
months (range 11 days–61 months). The median survival
for the 13 patients with unresected disease was 10 months,
whereas that for the 29 patients who underwent resection
was 20 months (P ¼ .0052, Figure 1). The 24 patients
who underwent resection of epithelial subtype tumors sur-
vived significantly longer than did the 5 patients with none-
pithelial disease (median survival 29 months vs 13 months,
P ¼ .006; Figure 2). The 15 patients who received higher
cisplatin doses (175–200 mg/m2) had a survival of 26
months, and the 14 patients who received lower doses
TABLE 1. Stage of disease, type of mesothelioma, margins and other
characteristics by side of resection (n ¼ 29)
Right side Left side
No. % No. %
16 55% 13 45%
Male 13 81% 9 69%
Epithelial type 12 75% 12 92%
Brigham and Women’s Hospital stage
1 2 13% 3 23%
2 6 38% 7 54%
3 8 50% 3 23%
N stage
0 8 50% 5 38%
1 1 6% 6 46%
Extrapleural nodes 7 44% 2 15%
Margins
Positive 12 80% 7 54%
Unable to be assessed 1 6% 0
TABLE 2. Morbidity and mortality among patients undergoing resection (n ¼ 29)
Common toxicity criteria grade
1 2 3 4 5 Total
Mortality 2 (7%)
Morbidities
Atrial fibrillation 0 0 18 1 0 19 (66%)
Non–Q wave myocardial infarction 0 0 0 1 0 1 (3%)
Pericarditis 0 8 0 0 0 8 (28%)
Respiratory failure 0 0 0 4 1 5 (17%)
Adult respiratory distress syndrome 0 0 0 3 1 4 (14%)
Tracheostomy/feeding tube NA NA NA NA NA 2 (7%)
Vocal cord injury 0 3 0 0 0 3 (10%)
Pneumonia 0 1 0 2 0 3 (10%)
Aspiration 0 0 0 1 0 1 (3%)
DVT and PE 0 0 8 DVT 1 PE, 1 DVTþPE 1 PE (fatal) 11 (31%)
Creatinine elevation 3 10 5 4 0 22 (76%)
Renal failure requiring dialysis 0 0 2 1 0 3 (10%)
Neuropathy (motor) 0 0 0 1 0 1 (3%)
Empyema 0 0 0 2 1 3 (10%)
Bronchopleural fistula 0 0 0 1 1 2 (7%)
Reoperations for bleeding,
patch failure, infections NA NA NA NA NA 6 (21%)
Data are expressed as numbers of patients. NA, Not applicable; DVT, deep venous thrombosis; PE, pulmonary embolism.
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.36). The 10 patients without positive surgical margins had
30-month median survival, whereas the 19 patients with pos-
itive margins had a 17-month median survival (P ¼ .410).
Patients with negative extrapleural lymph nodes survived
significantly longer as a subset. The 20 patients without
N2 disease had a median survival of 31 months, whereas
the 9 patients with N2 disease had a 14-month median sur-
vival (P ¼ .0115; Figure 3). The 18 patients with Brigham
and Women’s Hospital–Dana-Farber Cancer Institute stage
1 to 2 disease1 had a median survival of 35 months, whereas
the 11 patients with stage 3 disease had a 14-month median
survival (P ¼ .0022; Figure 4, A). Among the subset of pa-
tients with resected disease of epithelial type, the 16 patients
with Brigham and Women’s Hospital–Dana-Farber Cancer
Institute stage 1 to 2 disease had a 39-month median sur-
vival, versus 15 months for the 8 patients with stage 3 dis-
ease (P ¼ .0072; Figure 4, B).
Patterns of Recurrence
Radiographic or pathologically confirmed recurrence of
MPM was observed in 23 patients with resected disease
(79%), 3 of whom at the time of this analysis remained alive
at 52, 57, and 61 months. Three patients (10%) died without
radiographic or pathologic evidence of recurrence. Three pa-
tients (10%) were alive at the time of this analysis without
evidence of recurrence at 48, 50, and 51 months.
The median time to first recurrence among patients with
resected disease was 16 months. Patients with epithelial his-
tologic type had a 24-month median time to first recurrence,
whereas patients with nonepithelial histologic type had a
median time to first recurrence of 5 months (P¼ .0008). Pa-
tients with N2 nodes uninvolved with MPM had a 23-month
median time to first recurrence where as patients with N2
nodes involved with MPM had a median time to recurrence
of 9 months.
Initial recurrences involved the ipsilateral hemithorax
alone in 5 patients (17%), the abdomen alone in 7 patients
(24%), and the contralateral hemithorax in 3 patients
(10%). Several patients had recurrence simultaneously at
multiple sites. One patient (3%) had initial recurrence in
both the ipsilateral hemithorax and the abdomen, 4 patients
(14%) had initial recurrence in both the abdomen and the
TABLE 3. Renal toxicity at each dose level
Renal toxicity grade
Dose level Cisplatin (mg/m2) N 1 2 3 4
1 175 3 1 1 — —
2 200 3 — 1 1 1
3 175 9 1 4 1 2
4 150 2 — 1 1 —
5* 75 3 — 1 — —
6* 100 3 — 1 — —
7* 125 5 1 1 2 —
8* 100 1 — — — 1
Total 29 3 10 5 4
Data are expressed as numbers of patients. *Protocol revision.
FIGURE 1. All patients enrolled, survival by resection. Blue line repre-
sents resection; red line represents no resection.
FIGURE 2. All patients with resected disease, survival by cell type. Blue
line represents epithelial cell type; red line represents other types.
FIGURE 3. All patients with resected disease, survival by N2 status. Blue
line represents negative status; red line represents positive status.
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neous recurrence in all three cavities. Total recurrence in the
ipsilateral hemithorax was 31% (9 patients), total recurrence
in the abdomen was 52% (15 patients), and total recurrence
in the contralateral hemithorax was 32% (10 patients).
DISCUSSION
Renal toxicity is a major factor preventing escalation of
dose during IOHC when single-dose amifostine is used for
cytoprotection. Nine patients had grade 3 or greater creati-
nine elevation. Among these, 8 had reversible grade-3 or
grade-4 toxicity, and 1 patient had irreversible renal failure
and is alive on dialysis 4 years after the procedure with no
evidence of disease. Because the renal toxicity was not con-
sistently related to the cisplatin dose, we discontinued the
study and concluded that the cytoprotection regimen of sin-
gle-dose amifostine at 910 mg/m2 provided inadequate pro-
tection in the context of intracavitary cisplatin.
FIGURE 4. A, Patients with resected disease, survival by Brigham and
Women’s Hospital stage. Blue line represents stages 1 and 2; red line rep-
resents stage 3. B, Patients with resected epithelial disease, survival by Brig-
ham and Women’s Hospital stage. Blue line represents stages 1 and 2; red
line represents stage 3.
The Journal of Thoracic and CAlthough amifostine alone was an ineffective cytoprotec-
tive agent, it had no obvious adverse effect on the efficacy of
IOHC with cisplatin. The 100-fold preferential uptake of
amifostine by normal cells relative to tumor cells, as op-
posed to the direct covalent binding of sodium thiosulfate
to cisplatin in the circulating blood volume, provides more
selective cytoprotection, with preservation of the cisplatin’s
therapeutic benefit. This is consistent with other studies that
have used amifostine cytoprotection against platinum toxic-
ity.12-15,18 For example, Betticher and associates14 reported
that in a randomized phase II trial, addition of amifostine to
carboplatin therapy reduced thrombocytopenia duration and
hospitalization stay with no evidence of tumor protection by
amifostine. Similarly, Schiller and colleagues12 used ami-
fostine for cisplatin and vinblastine therapy for metastatic
non–small cell lung cancer, with an excellent response rate
and 17-month median survival. Addition of amifostine for
renal protection resulted in a 12% rate of reversible grade
3 renal toxicity. In contrast, sodium thiosulfate binds cova-
lently to inactivate cisplatin, providing excellent cytoprotec-
tion, but probably at the expense of some potential
therapeutic benefit.
Cardiac and pulmonary complications constituted the pri-
mary nonrenal morbidities, similar to our previous published
experience with EPP.1,17 The thrombotic morbidity has been
noted in the context of hyperthermia19-21 and is equivalent to
that in our previous IOHC studies.6,17 The mortality of 7%
is comparable to those in published reports of EPP without
IOHC.5
Although this study did not identify a dose at which ami-
fostine protected the kidney, many of the patients have had
extended survival relative to a historical control group. We
have previously reported our experience with trimodality
therapy involving EPP for MPM in a 183-patient cohort.
In that study, positive margins, positive extrapleural lymph
nodes, advanced stage of disease, and nonepithelial histo-
logic type were found to adversely affect survival in this co-
hort of patients. Patients with stage I and II disease reported
on here had a median survival of 32 months. This compares
favorably with our previous experience with patients not re-
ceiving IOHC.1
Additional studies will be required to determine the opti-
mal cytoprotective strategy for IOHC in this clinical setting.
Although agents such as sodium thiosulfate are highly effec-
tive, our experience has consistently shown a negative im-
pact of sodium thiosulfate on the therapeutic effect of
cisplatin. For example, one study of EPP conducted by our
group that used IOHC cisplatin with simultaneous infusion
of sodium thiosulfate did not show a dose effect on sur-
vival.17 In contrast, the pleurectomy study with IOHC cis-
platin followed by sodium thiosulfate infused after the
IOHC perfusion6 did show a dose effect on survival, sug-
gesting that concurrent sodium thiosulfate administration
may have attenuated the cisplatin therapeutic effect in the
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be to delay administration of sodium thiosulfate by a few
hours, instead of administering it immediately at the conclu-
sion of the chemotherapy perfusion, to determine whether
a further increase in therapeutic effect could be achieved
without increased renal toxicity.
The timing of amifostine administration is also critical to
effective cytoprotection. Amifostine infusion needs to be
initiated long enough before chemotherapy administration
to allow intracellular distribution.16 Clearly, a single 910-
mg/m2 amifostine dose was not sufficient to protect from cis-
platin renal toxicity, and we no longer use this strategy alone
for cytoprotection during IOHC. Further exploration of
cytoprotective strategies is needed, and multiple doses of
amifostine or a combination of amifostine and sodium thio-
sulfate may provide improved cytoprotection with greater
therapeutic benefit.22-24
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